These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 30308494)
1. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT. Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494 [TBL] [Abstract][Full Text] [Related]
2. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway. Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X Gene; 2019 May; 698():50-60. PubMed ID: 30822475 [TBL] [Abstract][Full Text] [Related]
3. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling. Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway. Zhu B; Wei Y Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323 [TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression. Liang Z; Ge Y; Li J; Bai Y; Xiao Z; Yan R; An G; Zhang D J Cancer Res Clin Oncol; 2024 Jul; 150(7):342. PubMed ID: 38980538 [TBL] [Abstract][Full Text] [Related]
6. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540 [TBL] [Abstract][Full Text] [Related]
7. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357 [TBL] [Abstract][Full Text] [Related]
8. IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling. Wei CX; Wong H; Xu F; Liu Z; Ran L; Jiang RD Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8169-8178. PubMed ID: 30556855 [TBL] [Abstract][Full Text] [Related]
9. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling. Duan HX; Li BW; Zhuang X; Wang LT; Cao Q; Tan LH; Qu GF; Xiao S Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G763-G773. PubMed ID: 30920845 [TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA AFAP1-AS1 Promoted Tumor Growth and Invasion in Cholangiocarcinoma. Lu X; Zhou C; Li R; Deng Y; Zhao L; Zhai W Cell Physiol Biochem; 2017; 42(1):222-230. PubMed ID: 28535506 [TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway. Hu X; Tan Z; Yang Y; Yang P J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284 [TBL] [Abstract][Full Text] [Related]
12. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma. Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195 [TBL] [Abstract][Full Text] [Related]
13. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression. Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell. Xiong GP; Zhang JX; Gu SP; Wu YB; Liu JF Neoplasma; 2012; 59(4):409-15. PubMed ID: 22489696 [TBL] [Abstract][Full Text] [Related]
15. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma. Poosekeaw P; Pairojkul C; Sripa B; Sa Ngiamwibool P; Iamsaard S; Sakonsinsiri C; Thanan R; Ungarreevittaya P PLoS One; 2021; 16(11):e0259075. PubMed ID: 34780466 [TBL] [Abstract][Full Text] [Related]
16. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma. Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468 [TBL] [Abstract][Full Text] [Related]
17. miR-181b-5p Promotes the Progression of Cholangiocarcinoma by Targeting PARK2 via PTEN/PI3K/AKT Signaling Pathway. Jiang ZL; Zhang FX; Zhan HL; Yang HJ; Zhang SY; Liu ZH; Jiang Y; Lv LZ; Ke RS Biochem Genet; 2022 Feb; 60(1):223-240. PubMed ID: 34169384 [TBL] [Abstract][Full Text] [Related]
18. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN. Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. Lu C; Shan Z; Hong J; Yang L Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966 [TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway. Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]